SC
RCKT icon

Stempoint Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Stempoint Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-270,983
Closed -$3.41M – 77
2024
Q4 		$3.41M Buy
+270,983
New +$4.08M 0.85% 37

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Stempoint Capital's RCKT Position: Q1 2025 in Review

Stempoint Capital sold out of Rocket Pharmaceuticals (RCKT) in Q1 2025, closing a stake of 270,983 shares — an estimated $3.41M sold.

Stempoint Capital first reported a position in RCKT in Q4 2024 and held it in 1 quarter. The position peaked at $3.41M in Q4 2024. 236 funds tracked by Wall St. Rank hold RCKT as of Q1 2025.

  • Stempoint Capital reported no remaining Rocket Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Stempoint Capital sold 270,983 Rocket Pharmaceuticals shares in Q1 2025, an estimated $3.41M.
  • Stempoint Capital first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Stempoint Capital's Rocket Pharmaceuticals position peaked at $3.41M in Q4 2024.
  • 236 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2025.

Based on Stempoint Capital's 13F filing for Q1 2025, filed 15 May 2025.